Systemic Monotherapy Treatments for Generalized Pustular Psoriasis: A Systematic Review
Generalized pustular psoriasis (GPP) is a rare but serious and difficult to treat cutaneous disease, with high morbidity and mortality rates. Despite the numerous treatment regimens available, the overall quality of evidence-based research is limited with a lack of an algorithmic approach available....
Gespeichert in:
Veröffentlicht in: | Journal of Cutaneous Medicine and Surgery 2018-11, Vol.22 (6), p.591-601 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 601 |
---|---|
container_issue | 6 |
container_start_page | 591 |
container_title | Journal of Cutaneous Medicine and Surgery |
container_volume | 22 |
creator | Zhou, Linghong Linda Georgakopoulos, Jorge R. Ighani, Arvin Yeung, Jensen |
description | Generalized pustular psoriasis (GPP) is a rare but serious and difficult to treat cutaneous disease, with high morbidity and mortality rates. Despite the numerous treatment regimens available, the overall quality of evidence-based research is limited with a lack of an algorithmic approach available. In this review, we aim to evaluate the current level of evidence regarding the efficacy and safety/tolerability of systemic monotherapies available in the treatment of GPP. A comprehensive MEDLINE, EMBASE, and PubMed search of clinical studies examining systemic monotherapy treatment options for GPP was conducted. In total, 31 studies met eligibility criteria. Described treatment modalities included retinoids, cyclosporine, biologics, and dapsone. Despite the lack of high-quality evidence or a well-accepted treatment algorithm for GPP, systemic retinoids, cyclosporine, biologics, and dapsone are all possible first-line agents, with retinoids being one of the best-supported treatment options and biologics as an emerging therapeutic field with great potential requiring additional data. However, the final choice of treatment should be considered within the unique context of each patient. |
doi_str_mv | 10.1177/1203475418773358 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2032797001</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_1203475418773358</sage_id><sourcerecordid>2032797001</sourcerecordid><originalsourceid>FETCH-LOGICAL-c431t-d1fcb139b3fd25ad1b214b11b00fb8d44ee2d63a3bae158d8cb91f657d1fa8553</originalsourceid><addsrcrecordid>eNp1kM1Lw0AQxRdRrFbvniTgxUt0J5vNJt5K0SpULFrxGHaTiabko-5ulPrXuyVVoeBplpnfe7PzCDkBegEgxCUElIWChxALwRiPd8gBRMB9ATTZdW839tfzATk0ZkEpBeDhPhkEiaAiEckBeXlaGYt1mXn3bdPaN9RyufLmGqWtsbHGK1rtTbBx_ar8wtybdcZ2ldTezLS6lKY0V97I612kdT6P-FHi5xHZK2Rl8HhTh-T55no-vvWnD5O78WjqZyED6-dQZApYoliRB1zmoAIIFYCitFBxHoaIQR4xyZRE4HEeZyqBIuLCCWXMORuS8953qdv3Do1N69JkWFWywbYzqUsgcJe6yx16toUu2k437ndpAFxEEMZJ7CjaU5lujdFYpEtd1lKvUqDpOvR0O3QnOd0Yd6rG_Ffwk7ID_B4w8hX_tv5r-A2Mk4my</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2157614898</pqid></control><display><type>article</type><title>Systemic Monotherapy Treatments for Generalized Pustular Psoriasis: A Systematic Review</title><source>Access via SAGE</source><source>MEDLINE</source><creator>Zhou, Linghong Linda ; Georgakopoulos, Jorge R. ; Ighani, Arvin ; Yeung, Jensen</creator><creatorcontrib>Zhou, Linghong Linda ; Georgakopoulos, Jorge R. ; Ighani, Arvin ; Yeung, Jensen</creatorcontrib><description>Generalized pustular psoriasis (GPP) is a rare but serious and difficult to treat cutaneous disease, with high morbidity and mortality rates. Despite the numerous treatment regimens available, the overall quality of evidence-based research is limited with a lack of an algorithmic approach available. In this review, we aim to evaluate the current level of evidence regarding the efficacy and safety/tolerability of systemic monotherapies available in the treatment of GPP. A comprehensive MEDLINE, EMBASE, and PubMed search of clinical studies examining systemic monotherapy treatment options for GPP was conducted. In total, 31 studies met eligibility criteria. Described treatment modalities included retinoids, cyclosporine, biologics, and dapsone. Despite the lack of high-quality evidence or a well-accepted treatment algorithm for GPP, systemic retinoids, cyclosporine, biologics, and dapsone are all possible first-line agents, with retinoids being one of the best-supported treatment options and biologics as an emerging therapeutic field with great potential requiring additional data. However, the final choice of treatment should be considered within the unique context of each patient.</description><identifier>ISSN: 1203-4754</identifier><identifier>EISSN: 1615-7109</identifier><identifier>DOI: 10.1177/1203475418773358</identifier><identifier>PMID: 29707979</identifier><language>eng</language><publisher>Los Angeles, CA: SAGE Publications</publisher><subject>Adult ; Drug therapy ; Evidence ; Female ; Humans ; Male ; Middle Aged ; Psoriasis ; Psoriasis - drug therapy ; Skin diseases ; Systematic review</subject><ispartof>Journal of Cutaneous Medicine and Surgery, 2018-11, Vol.22 (6), p.591-601</ispartof><rights>The Author(s) 2018</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c431t-d1fcb139b3fd25ad1b214b11b00fb8d44ee2d63a3bae158d8cb91f657d1fa8553</citedby><cites>FETCH-LOGICAL-c431t-d1fcb139b3fd25ad1b214b11b00fb8d44ee2d63a3bae158d8cb91f657d1fa8553</cites><orcidid>0000-0002-6844-2724</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/1203475418773358$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/1203475418773358$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,315,782,786,794,21826,27929,27931,27932,43628,43629</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29707979$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Zhou, Linghong Linda</creatorcontrib><creatorcontrib>Georgakopoulos, Jorge R.</creatorcontrib><creatorcontrib>Ighani, Arvin</creatorcontrib><creatorcontrib>Yeung, Jensen</creatorcontrib><title>Systemic Monotherapy Treatments for Generalized Pustular Psoriasis: A Systematic Review</title><title>Journal of Cutaneous Medicine and Surgery</title><addtitle>J Cutan Med Surg</addtitle><description>Generalized pustular psoriasis (GPP) is a rare but serious and difficult to treat cutaneous disease, with high morbidity and mortality rates. Despite the numerous treatment regimens available, the overall quality of evidence-based research is limited with a lack of an algorithmic approach available. In this review, we aim to evaluate the current level of evidence regarding the efficacy and safety/tolerability of systemic monotherapies available in the treatment of GPP. A comprehensive MEDLINE, EMBASE, and PubMed search of clinical studies examining systemic monotherapy treatment options for GPP was conducted. In total, 31 studies met eligibility criteria. Described treatment modalities included retinoids, cyclosporine, biologics, and dapsone. Despite the lack of high-quality evidence or a well-accepted treatment algorithm for GPP, systemic retinoids, cyclosporine, biologics, and dapsone are all possible first-line agents, with retinoids being one of the best-supported treatment options and biologics as an emerging therapeutic field with great potential requiring additional data. However, the final choice of treatment should be considered within the unique context of each patient.</description><subject>Adult</subject><subject>Drug therapy</subject><subject>Evidence</subject><subject>Female</subject><subject>Humans</subject><subject>Male</subject><subject>Middle Aged</subject><subject>Psoriasis</subject><subject>Psoriasis - drug therapy</subject><subject>Skin diseases</subject><subject>Systematic review</subject><issn>1203-4754</issn><issn>1615-7109</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kM1Lw0AQxRdRrFbvniTgxUt0J5vNJt5K0SpULFrxGHaTiabko-5ulPrXuyVVoeBplpnfe7PzCDkBegEgxCUElIWChxALwRiPd8gBRMB9ATTZdW839tfzATk0ZkEpBeDhPhkEiaAiEckBeXlaGYt1mXn3bdPaN9RyufLmGqWtsbHGK1rtTbBx_ar8wtybdcZ2ldTezLS6lKY0V97I612kdT6P-FHi5xHZK2Rl8HhTh-T55no-vvWnD5O78WjqZyED6-dQZApYoliRB1zmoAIIFYCitFBxHoaIQR4xyZRE4HEeZyqBIuLCCWXMORuS8953qdv3Do1N69JkWFWywbYzqUsgcJe6yx16toUu2k437ndpAFxEEMZJ7CjaU5lujdFYpEtd1lKvUqDpOvR0O3QnOd0Yd6rG_Ffwk7ID_B4w8hX_tv5r-A2Mk4my</recordid><startdate>20181101</startdate><enddate>20181101</enddate><creator>Zhou, Linghong Linda</creator><creator>Georgakopoulos, Jorge R.</creator><creator>Ighani, Arvin</creator><creator>Yeung, Jensen</creator><general>SAGE Publications</general><general>SAGE PUBLICATIONS, INC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-6844-2724</orcidid></search><sort><creationdate>20181101</creationdate><title>Systemic Monotherapy Treatments for Generalized Pustular Psoriasis: A Systematic Review</title><author>Zhou, Linghong Linda ; Georgakopoulos, Jorge R. ; Ighani, Arvin ; Yeung, Jensen</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c431t-d1fcb139b3fd25ad1b214b11b00fb8d44ee2d63a3bae158d8cb91f657d1fa8553</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Adult</topic><topic>Drug therapy</topic><topic>Evidence</topic><topic>Female</topic><topic>Humans</topic><topic>Male</topic><topic>Middle Aged</topic><topic>Psoriasis</topic><topic>Psoriasis - drug therapy</topic><topic>Skin diseases</topic><topic>Systematic review</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Zhou, Linghong Linda</creatorcontrib><creatorcontrib>Georgakopoulos, Jorge R.</creatorcontrib><creatorcontrib>Ighani, Arvin</creatorcontrib><creatorcontrib>Yeung, Jensen</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of Cutaneous Medicine and Surgery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Zhou, Linghong Linda</au><au>Georgakopoulos, Jorge R.</au><au>Ighani, Arvin</au><au>Yeung, Jensen</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Systemic Monotherapy Treatments for Generalized Pustular Psoriasis: A Systematic Review</atitle><jtitle>Journal of Cutaneous Medicine and Surgery</jtitle><addtitle>J Cutan Med Surg</addtitle><date>2018-11-01</date><risdate>2018</risdate><volume>22</volume><issue>6</issue><spage>591</spage><epage>601</epage><pages>591-601</pages><issn>1203-4754</issn><eissn>1615-7109</eissn><abstract>Generalized pustular psoriasis (GPP) is a rare but serious and difficult to treat cutaneous disease, with high morbidity and mortality rates. Despite the numerous treatment regimens available, the overall quality of evidence-based research is limited with a lack of an algorithmic approach available. In this review, we aim to evaluate the current level of evidence regarding the efficacy and safety/tolerability of systemic monotherapies available in the treatment of GPP. A comprehensive MEDLINE, EMBASE, and PubMed search of clinical studies examining systemic monotherapy treatment options for GPP was conducted. In total, 31 studies met eligibility criteria. Described treatment modalities included retinoids, cyclosporine, biologics, and dapsone. Despite the lack of high-quality evidence or a well-accepted treatment algorithm for GPP, systemic retinoids, cyclosporine, biologics, and dapsone are all possible first-line agents, with retinoids being one of the best-supported treatment options and biologics as an emerging therapeutic field with great potential requiring additional data. However, the final choice of treatment should be considered within the unique context of each patient.</abstract><cop>Los Angeles, CA</cop><pub>SAGE Publications</pub><pmid>29707979</pmid><doi>10.1177/1203475418773358</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-6844-2724</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1203-4754 |
ispartof | Journal of Cutaneous Medicine and Surgery, 2018-11, Vol.22 (6), p.591-601 |
issn | 1203-4754 1615-7109 |
language | eng |
recordid | cdi_proquest_miscellaneous_2032797001 |
source | Access via SAGE; MEDLINE |
subjects | Adult Drug therapy Evidence Female Humans Male Middle Aged Psoriasis Psoriasis - drug therapy Skin diseases Systematic review |
title | Systemic Monotherapy Treatments for Generalized Pustular Psoriasis: A Systematic Review |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-05T12%3A05%3A15IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Systemic%20Monotherapy%20Treatments%20for%20Generalized%20Pustular%20Psoriasis:%20A%20Systematic%20Review&rft.jtitle=Journal%20of%20Cutaneous%20Medicine%20and%20Surgery&rft.au=Zhou,%20Linghong%20Linda&rft.date=2018-11-01&rft.volume=22&rft.issue=6&rft.spage=591&rft.epage=601&rft.pages=591-601&rft.issn=1203-4754&rft.eissn=1615-7109&rft_id=info:doi/10.1177/1203475418773358&rft_dat=%3Cproquest_cross%3E2032797001%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2157614898&rft_id=info:pmid/29707979&rft_sage_id=10.1177_1203475418773358&rfr_iscdi=true |